Last reviewed · How we verify
NCT03167216
Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction
EARLY_PHASE1 trial testing Cromolyn Sodium in Chronic Prostatitis With Chronic Pelvic Pain Syndrome in 20 participants. Completed in 30 June 2022.
1 April 2022
Quick facts
| Lead sponsor | Northwestern University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 1 August 2017 |
| Primary completion | 1 April 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cromolyn Sodium — full drug profile →
- Cetirizine Hydrochloride — full drug profile →
Conditions studied
- Chronic Prostatitis With Chronic Pelvic Pain Syndrome — all drugs for Chronic Prostatitis With Chronic Pelvic Pain Syndrome →
Sponsor
Northwestern University
Who can join
Adults 21 to 80, male only, with Chronic Prostatitis With Chronic Pelvic Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate inhibition of mast cells and the histamine 1 receptor (H1R) for treatment of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03167216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cromolyn Sodium
Trials testing the same drug.
- NCT05077917 — Cromolyn Sodium for Treatment of COVID-19 Pneumonia · Phase 3 · terminated
Other recruiting trials for Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Currently open trials in the same condition.
- NCT06299683 — Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment · NA · recruiting
- NCT06345014 — The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome · Phase 4 · recruiting
Other Northwestern University trials
Trials by the same sponsor.
- NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
- NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
- NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
- NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
- NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03167216 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwestern University
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03167216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing